| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/04/2006 | WO2006045430A1 Imidazo-benzodiazepine derivatives |
| 05/04/2006 | WO2006045429A1 Halogen substituted benzodiazepine derivatives |
| 05/04/2006 | WO2006045416A1 Quinoline derivatives |
| 05/04/2006 | WO2006045298A2 Treatment of the consequences of alcohol abuse hepatitis pancreatitis |
| 05/04/2006 | WO2006045255A1 Method of manufacturing (s)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine) |
| 05/04/2006 | WO2006045204A1 Aryl sulfonic pyridoxines as antiplatelet agents |
| 05/04/2006 | WO2006045203A1 Substituted pyridoxines as anti-platelet agents |
| 05/04/2006 | WO2006045202A1 Antisense oligonucleotides for treating allergy and neoplastic cell proliferation |
| 05/04/2006 | WO2006045156A1 Therapy for multi-drug resistant microorganisms |
| 05/04/2006 | WO2006038931A3 Odor-reducing quinone compounds |
| 05/04/2006 | WO2006036512A3 Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same |
| 05/04/2006 | WO2006036497A3 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
| 05/04/2006 | WO2006033913A3 Bis (thio-hydrazide amides) for treament of hyperplasia |
| 05/04/2006 | WO2006032537A3 Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
| 05/04/2006 | WO2006031878A3 Imidazoquinoline compounds |
| 05/04/2006 | WO2006030438A3 Use of tellurium compounds for inhibition of interleukin-converting enzyme |
| 05/04/2006 | WO2006027628A3 Naphthalimide derivatives as antiviral agents |
| 05/04/2006 | WO2006026619A3 Inhibition of viruses using rnase h inhibitors |
| 05/04/2006 | WO2006025889A3 Inhibition of atherosclerosis by diindolylmethane analogs |
| 05/04/2006 | WO2006024949A3 Controlled release dosage forms combining immediate release and sustained release of low-solubility drug |
| 05/04/2006 | WO2006023630A3 The use of n-aryl diazaspiracyclic compounds in the treatment of addiction |
| 05/04/2006 | WO2006023573A3 Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers |
| 05/04/2006 | WO2006021454A3 Pyrimidine derivatives |
| 05/04/2006 | WO2006020850A3 Pharmaceutical composition and method for treating neurodegenerative disorders |
| 05/04/2006 | WO2006018718A3 Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
| 05/04/2006 | WO2006017823A3 Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors |
| 05/04/2006 | WO2006017639A3 Crystalline polymorph of pipindoxifene hydrochloride monohydrate |
| 05/04/2006 | WO2006017522A3 Use of antisense oligonucleotides to effect translation modulation |
| 05/04/2006 | WO2006015183A3 Pharmaceutical compositions for treating disorders of the skin |
| 05/04/2006 | WO2006013227A8 Methylamine risks and treatment with n-derivatives of hyperactivity, depression and alcoholism |
| 05/04/2006 | WO2006013210A3 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| 05/04/2006 | WO2006012616A3 Therapeutic use of anti-tf-antigen antibody |
| 05/04/2006 | WO2006012521A3 Treatment for ocular disease |
| 05/04/2006 | WO2006012395A3 Peptidase inhibitors |
| 05/04/2006 | WO2006012227A3 Amido compounds and their use as pharmaceuticals |
| 05/04/2006 | WO2006010040A3 Antibacterial agents |
| 05/04/2006 | WO2006007378A3 Pyrrolotriazine kinase inhibitors |
| 05/04/2006 | WO2006006172A3 Use of anti-amyloid agents for treating and typing pathogen infections |
| 05/04/2006 | WO2006005726A3 Heterocyclic compounds |
| 05/04/2006 | WO2006005464A3 Dietary supplements comprising prebiotics and fatty acid |
| 05/04/2006 | WO2006003290A3 Sulphated depolymerised derivatives of exopolysaccharides (eps), preparation and uses thereof |
| 05/04/2006 | WO2006003289A3 Sulphated polysaccharide derivatives for modulating angiogenesis |
| 05/04/2006 | WO2006002918A3 Use of trisubstituted benzopyranones |
| 05/04/2006 | WO2006002348A3 Solid and crystalline ibandronic acid |
| 05/04/2006 | WO2006002102A3 Spirocyclic compounds useful as modulators of nuclear hormone receptor function |
| 05/04/2006 | WO2006002099A3 Factor xa inhibitors |
| 05/04/2006 | WO2006000441A3 Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
| 05/04/2006 | WO2005123731A3 Pyrrolopyridine derivatives and their use as crth2 antagonists |
| 05/04/2006 | WO2005123718A3 Benzimidazolone carboxylic acid derivatives |
| 05/04/2006 | WO2005123108A3 Advanced vitamins and protein based nutritional supplements |
| 05/04/2006 | WO2005118777A3 Novel saccharothrix strain and antibiotics derived therefrom, i.e. mutactimycins and aldgamycins |
| 05/04/2006 | WO2005117811A3 Physiological cooling compositions |
| 05/04/2006 | WO2005115336A3 Sprayable formulations for the treatment of acute inflammatory skin conditions |
| 05/04/2006 | WO2005115332A3 Heat sterilization of glucocorticosteroids |
| 05/04/2006 | WO2005115150A3 Novel lysophosphatidic acid receptor selective antagonists |
| 05/04/2006 | WO2005113016A3 Modulation of glucose-6-phosphatase translocase expression |
| 05/04/2006 | WO2005112965A3 Botanical anti-inflammatory compositions and methods |
| 05/04/2006 | WO2005112938A3 Disalt inhibitors of il-12 production |
| 05/04/2006 | WO2005112902A3 Medicinal aerosol formulation products with improved chemical stability |
| 05/04/2006 | WO2005112646A3 Treatment of diet-related conditions using phospholipase-a2 inhibitors comprising indoles and related compounds |
| 05/04/2006 | WO2005110448A3 Nutritional composition for increasing creatine uptake in skeletal muscle |
| 05/04/2006 | WO2005110398A3 Pharmaceutical solution formulations containing 17-aag |
| 05/04/2006 | WO2005110395A8 System and device for magnetic drug targeting with magnetic drug carrier particles |
| 05/04/2006 | WO2005109987A3 3-(((4-phenyl)-piperazine-1-yl)-alkyl)-3-alkyl-1, 3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders |
| 05/04/2006 | WO2005107462A3 Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate |
| 05/04/2006 | WO2005106492A3 Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3) |
| 05/04/2006 | WO2005105043A3 Pharmaceutical compositions |
| 05/04/2006 | WO2005096704B1 Cholesterol lowering composition |
| 05/04/2006 | WO2005094786A3 Coated tablet formulation and method |
| 05/04/2006 | WO2005094774A8 Skin lightening compositions comprising goya (momordica charantia) and pine extract |
| 05/04/2006 | WO2005089750A3 Use of metronidazole for preparing a pharmaceutical composition for treating pathologies related to the b-type receptor of interleukin 8 and/or to a pacap type 1 receptor |
| 05/04/2006 | WO2005089749A3 Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous vascularisation disorder |
| 05/04/2006 | WO2005087017A3 Compositions comprising reverse isomers of conjugated linoleic acid |
| 05/04/2006 | WO2005082345A3 Targeting the reverse mode of the na+/ca2+ exchanger for the treatment of neurodegenerative conditions such as alzheimers and parkinsons diseases, multiple sclerosis and amyotropic lateral sclerosis; diabetic retinopathy, epilepsy and ischemia |
| 05/04/2006 | WO2005082340A3 Modulation of inflammatory and metastatic processes |
| 05/04/2006 | WO2005082042A3 Therapeutic methods employing nitric oxide precursors |
| 05/04/2006 | WO2005080325A3 Sulfur-containing compositions and processes for making same |
| 05/04/2006 | WO2005074958B1 Use of an extract of pueraria tuberosa for the treatment of diabetes type 2 |
| 05/04/2006 | WO2005070901A3 Pyrimidyl phosphonate antiviral compounds and methods of use |
| 05/04/2006 | WO2005070398A8 Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents |
| 05/04/2006 | WO2005063169A3 Medical lipolysis of fat accumulations |
| 05/04/2006 | WO2005062860A3 New sunscreen compounds and compositions containing same and methods for use thereof |
| 05/04/2006 | WO2005060665A8 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors |
| 05/04/2006 | WO2005053657A3 Coated tablet containing venlafaxin or its salts with controlled release |
| 05/04/2006 | WO2005034845A8 Compositions and methods for treatment of cancer |
| 05/04/2006 | WO2005011583A8 Treatment of allergic rhinitis and asthma |
| 05/04/2006 | WO2004037972A3 Endogenous retrovirus up-regulated in prostate cancer |
| 05/04/2006 | WO2004004708A9 A pharmaceutical composition useful for treating chronic myeloid leukemia |
| 05/04/2006 | WO2003020911A3 Human schizophrenia gene |
| 05/04/2006 | US20060094902 Amino acid analogues |
| 05/04/2006 | US20060094880 Producing such as 1-{2-[2-(3,4-dimethoxy-phenyl)-ethoxy]-cyclohexyl}-pyrrolidin-3-ol; antiarrhythmia agents |
| 05/04/2006 | US20060094879 5-{4-[1-(2-Ethoxyethyl)-1H-indol-3-yl]piperidin-1-ylmethyl}-2-methoxybenzoic acid; histamine H1 antagonists; bronchial dialtors; asthma; allergic rhinitis; conjunctivitis; dermatitis; urticaria; selective antiallergic effects so less side effect reduction and lower dosage |
| 05/04/2006 | US20060094874 Novel substituted aryl alkenoic acid heterocyclic amides |
| 05/04/2006 | US20060094791 Aminated polyamines |
| 05/04/2006 | US20060094790 Use of sphingosine kinase activator as skin disease treating agent and method for treating skin diseases using the same |
| 05/04/2006 | US20060094789 Alpha- and beta-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors |
| 05/04/2006 | US20060094788 Prostaglandin derivatives |
| 05/04/2006 | US20060094787 Pharmaceutical composition comprising 5-methyl-2-2'(chloro-6'-fluoroanilino) phenylacetic acid |
| 05/04/2006 | US20060094786 Treating syndrome X with substituted tetralins and indanes |
| 05/04/2006 | US20060094785 Use of amino acids for treatment of various conditions |